0001209191-24-004016.txt : 20240227
0001209191-24-004016.hdr.sgml : 20240227
20240227170315
ACCESSION NUMBER: 0001209191-24-004016
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240223
FILED AS OF DATE: 20240227
DATE AS OF CHANGE: 20240227
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HALE DAVID F
CENTRAL INDEX KEY: 0001024004
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-50549
FILM NUMBER: 24688165
MAIL ADDRESS:
STREET 1: 1042-B NORTH EL CAMINO REAL, SUITE 430
CITY: ENCINITAS
STATE: CA
ZIP: 92024
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Oncternal Therapeutics, Inc.
CENTRAL INDEX KEY: 0001260990
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 621715807
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12230 EL CAMINO REAL
STREET 2: SUITE 230
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: (858) 434-1113
MAIL ADDRESS:
STREET 1: 12230 EL CAMINO REAL
STREET 2: SUITE 230
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
FORMER COMPANY:
FORMER CONFORMED NAME: GTX INC /DE/
DATE OF NAME CHANGE: 20030822
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2024-02-23
0
0001260990
Oncternal Therapeutics, Inc.
ONCT
0001024004
HALE DAVID F
12230 EL CAMINO REAL, SUITE 230
SAN DIEGO
CA
92130
1
0
0
0
0
Common Stock
2024-02-23
4
P
0
714
9.04
A
714
D
Common Stock
2024-02-23
4
P
0
266
9.04
A
29673
I
By Hale BioPharma Ventures, LLC
Common Stock
917
I
By Hale Trading Company
The shares of common stock were acquired directly from another director of the Issuer, Robert James Wills, in a private sale. The price per share was based on the closing price of the Issuer's common stock on February 23, 2024.
The number of shares of common stock in this form have been adjusted to reflect the Issuer's 1-for-20 reverse stock split effective as of January 8, 2024.
/s/Chase C. Leavitt, Attorney-in-fact
2024-02-27